For over 30 years Skip has been advising companies on business strategy, product commercialization, R&D planning and business development in the biotech, pharmaceutical and medical products industries. Skip is a member of the College Corporation at the Massachusetts College of Pharmacy and Health Sciences where he earned his BS in Pharmacy. He continues to maintain his license to practice pharmacy. And he serves on the Board of Overseers for Mount Auburn Hospital. Skip earned his MBA at the Amos Tuck School at Dartmouth College.
Currently, Skip serves as part-time Vice President for Stemnion, Inc., a Pittsburgh-based biotechnology company developing novel biologic products for tissue healing. In his personal senior management advisory practice, he works with senior management, boards of directors and investors on a range of strategy and organizational issues in the industry. He is an advisor to Red Sky Partners and Locust Walk Partners. He also involved with several early-stage entrepreneurs focusing on company formation, strategy and fundraising.
Skip has a long-standing interest in the neuroscience field. He serves on the Board of the Michael J. Fox Foundation for Parkinson’s Research and chairs the Research Committee which oversees $70 million in academic and industry sponsored research each year. He also serves on the Industry Advisory Committee for the Brain Tumor Society.
Until recently Skip was a Managing Director at Health Advances where he continues as an advisor and Partner, Emeritus. Joining in 1997, Skip helped create a leading life-science focused management consulting firm with over 100 professional staff. Skip’s practice included Fortune 500 companies, venture-backed start-up companies and not-for-profit disease foundations and leading academic centers.
Prior to joining Health Advances, as Vice President for Commercial Development at the Massachusetts Biotechnology Research Institute (MBRI), Skip was involved in the founding of seven life sciences companies. He also created a unique academic technology licensing office representing eight academic research institutions and representing over $200 million in research. Institutions included Tufts University, including Tufts Medical School, Tufts Veterinary School and Tufts School of Bioengineering, Worcester Polytechnic Institute, The Worcester Foundation for Experimental Biology, Boston Biomedical Research and the Marine Biology Laboratory at Woods Hole. He helped found and served on the Board of t-Breeders, a cellular therapy company eventually purchased by Perkin Elmer.
Prior to MBRI, Skip was Vice President and Director of Worldwide Healthcare Consulting at Arthur D. Little, Inc. where his professional work involved technology planning, R&D management, and strategic alliances. Skip also worked in manufacturing and quality assurance for the sterile parenteral business at AstraZeneca plc.